PT  - JOURNAL ARTICLE
AU  - HIROSHI TSUBAMOTO
AU  - TAKASHI SONODA
AU  - SHINICHI IKUTA
AU  - SATOSHI TANI
AU  - KAYO INOUE
AU  - NAOKI YAMANAKA
TI  - Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting
DP  - 2015 Jul 01
TA  - Anticancer Research
PG  - 4191--4196
VI  - 35
IP  - 7
4099  - http://ar.iiarjournals.org/content/35/7/4191.short
4100  - http://ar.iiarjournals.org/content/35/7/4191.full
SO  - Anticancer Res2015 Jul 01; 35
AB  - Background: We evaluated chemotherapy with itraconazole (a common anti-fungal agent that is a potent inhibitor of the Hedgehog pathway, P-glycoprotein, and angiogenesis) for treating progressive pancreatic cancer. Patients and Methods: We retrospectively reviewed the medical charts of patients with histologically-diagnosed pancreatic cancer who had received first- or second-line chemotherapy and subsequent chemotherapy with itraconazole. Results: A total of 38 patients received docetaxel (35 mg/m2), gemcitabine (1,000 mg/m2), and carboplatin (area under the curve, 4 mg/min/ml) on day 1 and oral itraconazole solution (400 mg) on days −2 to 2, repeated every 2 weeks. One complete response and 13 partial responses were observed, for a response rate of 37%. Eight (21%) patients experienced febrile neutropenia. The median overall survival was 11.4 months (95% confidence interval=8.5-21.2 months). Conclusion: Combination chemotherapy with itraconazole is promising for prolonging overall survival, with acceptable toxicities in the second-line setting of pancreatic cancer.